Rheumatoid Arthritis Drugs Market – Global Industry Analysis And Forecast (2022-2029)


Rheumatoid Arthritis Drugs Market is expected to grow at a CAGR of 4.50% during the forecast period and the market size is expected to reach nearly US$ 36.10 Bn by 2029.

Rheumatoid Arthritis Drugs Market Drivers and Restrains:

Rheumatoid arthritis (RA) is an autoimmune disorder that causes pain and inflammation in the joints. Rheumatoid arthritis disease mostly affects the joints along with articular tissues and extra articular organs such as hands, wrists, elbows, knees, and ankles. The rheumatoid arthritis also disturbs the cardiac and respiratory system. It is known as a systemic disease. It commonly affects almost xx% of the geriatric population. It mostly onsets during middle age, and women are affected xx times as frequently as men. As there is no permanent cure for RA, the goals of the treatment are to decrease pain, reduce inflammation, prevent bone deformity, and improve a person’s whole body function. Several therapeutics and medication have been developed to relieve and treat the symptoms of rheumatoid arthritis in recent years.

Global Rheumatoid Arthritis Drugs Market

To know about the Research Methodology :- Request Free Sample Report

The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

The rheumatoid arthritis drugs market has driven by factors, which are rise in incidences of rheumatoid arthritis and upsurge in geriatric population. Additionally, transition from symptom management to slowing the progression of the disease further impells the market growth. However, side effects associated with the medication and higher cost of biologics & biosimilars are restraining the market growth at global level. The developments in the field of biosimilars and novel biologics are expected to offer lucrative opportunities for the growth of the RA drugs market. Demand for development of newer and biotechnologically enhanced products such as biologics and biosimilar is rising worldwide, owing to the treatment efficiency of drugs. Hence, major players operating in the rheumatoid arthritis drugs market are financing in research and development programs in order to develop novel drugs. Rise in investment in research and development programs by key players of the market is expected to boost the market significantly during the forecast period.

Rheumatoid Arthritis Drugs Market Segment Analysis:

Based on the drug type, the rheumatoid arthritis drugs market has been segmented into Disease-modifying anti-rheumatic drugs (DMARDs), Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and Biologic response modifiers (biologics). In term of revenue, the biologics segment held the dominant market share in 2021, owing to the considerably high cost of these medicine and the wide usage of drugs in severe rheumatoid disease. Biotechnological research and developments in rheumatoid arthritis drugs are likely to increase the biologic drugs segment growth in the near future. NSAIDs are mostly used for the symptomatic treatment of rheumatic disorders. DMARDs are considered as the gold standard for the treatment of moderate to severe rheumatoid arthritis.

Based on the distribution channel, the rheumatoid arthritis drugs market has been segmented into Hospital pharmacy, Retail pharmacy and Online pharmacy. The hospital pharmacy segment is projected to grow at the largest CAGR of xx% during the forecast period, owing to the increase in number of hospitals and rise in preference of the geriatric patient population to undergo treatment at hospitals.

Rheumatoid Arthritis Drugs Market Regional Insights:

Geographically, the rheumatoid arthritis drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the rheumatoid arthritis drugs market in 2021 owing to the high rate of adoption of biologic drugs and high health care expenditure in the region. The market in Asia Pacific is expected to expand at a high CAGR of xx% during the forecast period due to Increase in the incidences of rheumatoid arthritis disease and increasing health care expenditure in the region. Moreover, low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to Asia Pacific from across the world. Developed countries witnessed high rates of aging as compared to the developing countries. This is attributed to improved health care infrastructure, reimbursement policies, and advancement in health care facilities in these countries

A report covers the recent development for the rheumatoid arthritis drugs market like Takeda Pharmaceuticals financed US$ xx Bn in research and development activities. According to a yearly report published by GlaxoSmithKline plc, the company partnered with more than 1,500 companies and other academic organizations across the world for the development of novel drugs.

Rheumatoid Arthritis Drugs Market Competitive landscape

Major Key players operating in this market are AbbVie Inc., Boehringer Ingelheim GmbH, Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer, Inc. Manufacturers in the rheumatoid arthritis drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present comprehensive analysis of rheumatoid arthritis drugs market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding rheumatoid arthritis drugs market dynamics, structure by analyzing the market segments, and project the rheumatoid arthritis drugs market size. Clear representation of competitive analysis of key players by drug type, price, financial position, product portfolio, growth strategies, and regional presence in the rheumatoid arthritis drugs market make the report investor’s guide.

Rheumatoid Arthritis Drugs Market Scope: Inquire before buying






Global Rheumatoid Arthritis Drugs Market




Report Coverage
Details




Base Year:
2021
Forecast Period:
2022-2029




Historical Data:
2017 to 2021
Market Size in 2021:
US $ 25.38 Bn.




Forecast Period 2022 to 2029 CAGR:
4.50%
Market Size in 2029:
US $ 36.10 Bn.




 Segments Covered:
by Drug type
• Disease-modifying anti-rheumatic drugs (DMARDs)
• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Corticosteroids
• Biologic response modifiers (biologics)




by Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy






Rheumatoid Arthritis Drugs Market, by Region:

• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa

Rheumatoid Arthritis Drugs Market,  key Players:

• AbbVie Inc.
• Boehringer Ingelheim GmbH
• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Pfizer, Inc.
• Johnson & Johnsons Services, Inc
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Celegene Corporations
• MedImmune, LLC
• Takeda Pharmaceutical Company Ltd.
• Biogen Inc.
• Celltrion Inc.
• Janssen Biotech, Inc.
• Amgen, Inc.
• Eli Lily and company
• Merck & Co. Inc
• UCB S.A.
• Sobi, Inc.
• Gilead Science Inc.

Frequently Asked Questions:

1. Which region has the largest share in Global Rheumatoid Arthritis Drugs Market?
Ans: North America region helds the highest share in 2021.

2. What is the growth rate of Global Rheumatoid Arthritis Drugs Market?
Ans: The Global Rheumatoid Arthritis Drugs Market is growing at a CAGR of 4.50% during forecasting period 2022-2029.

3. What is scope of the Global Rheumatoid Arthritis Drugs market report?
Ans: Global Rheumatoid Arthritis Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Rheumatoid Arthritis Drugs market?
Ans: The important key players in the Global Rheumatoid Arthritis Drugs Market are-
AbbVie Inc,Boehringer Ingelheim GmbH,Novartis AG,Regeneron Pharmaceuticals, Inc.,Pfizer, Inc,Johnson & Johnsons Services, Inc,Bristol-Myers Squibb Company,F. Hoffmann-La Roche Ltd.,Celegene Corporations,MedImmune, LLC,Takeda Pharmaceutical Company Ltd.,Biogen Inc,Celltrion Inc,Janssen Biotech, Inc,Amgen, Inc,Eli Lily and company,Merck & Co. Inc,UCB S.A,Sobi, Inc,Gilead Science Inc,

5. What is the study period of this market?
Ans: The Global Rheumatoid Arthritis Drugs Market is studied from 2021 to 2029. 




Rheumatoid Arthritis Drugs Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Rheumatoid Arthritis Drugs Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
4.8. Patent Registration

5. Supply Side and Demand Side Indicators
6. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast
6.1. Global Rheumatoid Arthritis Drugs Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Drug Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
7.4. Global Rheumatoid Arthritis Drugs Market Size (US$ Bn) Forecast, by Drug Type
7.5. Global Rheumatoid Arthritis Drugs Market Analysis, by Drug Type
7.6. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type

8. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
8.4. Global Rheumatoid Arthritis Drugs Market Size (US$ Bn) Forecast, by Distribution Channel
8.5. Global Rheumatoid Arthritis Drugs Market Analysis, by Distribution Channel
8.6. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel

9. Global Rheumatoid Arthritis Drugs Market Analysis, by Region
9.1. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Region
9.2. Global Rheumatoid Arthritis Drugs Market Size (US$ Bn) Forecast, by Region
9.3. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Region

10. North America Rheumatoid Arthritis Drugs Market Analysis
10.1. Key Findings
10.2. North America Rheumatoid Arthritis Drugs Market Overview
10.3. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
10.4. North America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.5. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
10.6. North America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
10.6.1. Disease-modifying anti-rheumatic drugs (DMARDs)
10.6.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
10.6.3. Corticosteroids
10.6.4. Biologic response modifiers (biologics)
10.7. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
10.8. North America Rheumatoid Arthritis Drugs Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Rheumatoid Arthritis Drugs Market Analysis, by Country
10.10. U.S. Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
10.10.1. Hospital Pharmacy
10.10.2. Retail Pharmacy
10.10.3. Online Pharmacy
10.11. U.S. Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
10.11.1. Disease-modifying anti-rheumatic drugs (DMARDs)
10.11.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
10.11.3. Corticosteroids
10.11.4. Biologic response modifiers (biologics)
10.12. Canada Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
10.12.1. Hospital Pharmacy
10.12.2. Retail Pharmacy
10.12.3. Online Pharmacy
10.13. Canada Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
10.13.1. Disease-modifying anti-rheumatic drugs (DMARDs)
10.13.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
10.13.3. Corticosteroids
10.13.4. Biologic response modifiers (biologics)
10.14. North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis
10.14.1. By Drug Type
10.14.2. By Distribution Channel
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Development

11. Europe Rheumatoid Arthritis Drugs Market Analysis
11.1. Key Findings
11.2. Europe Rheumatoid Arthritis Drugs Market Overview
11.3. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
11.4. Europe Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy
11.4.3. Online Pharmacy
11.5. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
11.6. Europe Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
11.6.1. Disease-modifying anti-rheumatic drugs (DMARDs)
11.6.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
11.6.3. Corticosteroids
11.6.4. Biologic response modifiers (biologics)
11.7. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
11.8. Europe Rheumatoid Arthritis Drugs Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Rheumatoid Arthritis Drugs Market Analysis, by Country
11.10. Germany Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
11.10.1. Hospital Pharmacy
11.10.2. Retail Pharmacy
11.10.3. Online Pharmacy
11.11. Germany Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
11.11.1. Disease-modifying anti-rheumatic drugs (DMARDs)
11.11.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
11.11.3. Corticosteroids
11.11.4. Biologic response modifiers (biologics)
11.12. U.K. Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
11.12.1. Hospital Pharmacy
11.12.2. Retail Pharmacy
11.12.3. Online Pharmacy
11.13. U.K. Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
11.13.1. Disease-modifying anti-rheumatic drugs (DMARDs)
11.13.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
11.13.3. Corticosteroids
11.13.4. Biologic response modifiers (biologics)
11.14. France Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
11.14.1. Hospital Pharmacy
11.14.2. Retail Pharmacy
11.14.3. Online Pharmacy
11.15. France Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
11.15.1. Disease-modifying anti-rheumatic drugs (DMARDs)
11.15.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
11.15.3. Corticosteroids
11.15.4. Biologic response modifiers (biologics)
11.16. Italy Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
11.16.1. Hospital Pharmacy
11.16.2. Retail Pharmacy
11.16.3. Online Pharmacy
11.17. Italy Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
11.17.1. Disease-modifying anti-rheumatic drugs (DMARDs)
11.17.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
11.17.3. Corticosteroids
11.17.4. Biologic response modifiers (biologics)
11.18. Spain Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
11.18.1. Hospital Pharmacy
11.18.2. Retail Pharmacy
11.18.3. Online Pharmacy
11.19. Spain Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
11.19.1. Disease-modifying anti-rheumatic drugs (DMARDs)
11.19.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
11.19.3. Corticosteroids
11.19.4. Biologic response modifiers (biologics)
11.20. Rest of Europe Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
11.20.1. Hospital Pharmacy
11.20.2. Retail Pharmacy
11.20.3. Online Pharmacy
11.21. Rest of Europe Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
11.21.1. Disease-modifying anti-rheumatic drugs (DMARDs)
11.21.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
11.21.3. Corticosteroids
11.21.4. Biologic response modifiers (biologics)
11.22. Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis
11.22.1. By Drug Type
11.22.2. By Distribution Channel
11.23. PEST Analysis
11.24. Key Trend
11.25. Key Development

12. Asia Pacific Rheumatoid Arthritis Drugs Market Analysis
12.1. Key Findings
12.2. Asia Pacific Rheumatoid Arthritis Drugs Market Overview
12.3. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
12.4. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy
12.4.3. Online Pharmacy
12.5. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
12.6. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
12.6.1. Disease-modifying anti-rheumatic drugs (DMARDs)
12.6.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
12.6.3. Corticosteroids
12.6.4. Biologic response modifiers (biologics)
12.7. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
12.8. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Rheumatoid Arthritis Drugs Market Analysis, by Country
12.10. China Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
12.10.1. Hospital Pharmacy
12.10.2. Retail Pharmacy
12.10.3. Online Pharmacy
12.11. China Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
12.11.1. Disease-modifying anti-rheumatic drugs (DMARDs)
12.11.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
12.11.3. Corticosteroids
12.11.4. Biologic response modifiers (biologics)
12.12. India Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
12.12.1. Hospital Pharmacy
12.12.2. Retail Pharmacy
12.12.3. Online Pharmacy
12.13. India Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
12.13.1. Disease-modifying anti-rheumatic drugs (DMARDs)
12.13.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
12.13.3. Corticosteroids
12.13.4. Biologic response modifiers (biologics)
12.14. Japan Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
12.14.1. Hospital Pharmacy
12.14.2. Retail Pharmacy
12.14.3. Online Pharmacy
12.15. Japan Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
12.15.1. Disease-modifying anti-rheumatic drugs (DMARDs)
12.15.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
12.15.3. Corticosteroids
12.15.4. Biologic response modifiers (biologics)
12.16. ASEAN Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
12.16.1. Hospital Pharmacy
12.16.2. Retail Pharmacy
12.16.3. Online Pharmacy
12.17. ASEAN Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
12.17.1. Disease-modifying anti-rheumatic drugs (DMARDs)
12.17.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
12.17.3. Corticosteroids
12.17.4. Biologic response modifiers (biologics)
12.18. Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
12.18.1. Hospital Pharmacy
12.18.2. Retail Pharmacy
12.18.3. Online Pharmacy
12.19. Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
12.19.1. Disease-modifying anti-rheumatic drugs (DMARDs)
12.19.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
12.19.3. Corticosteroids
12.19.4. Biologic response modifiers (biologics)
12.20. Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis
12.20.1. By Drug Type
12.20.2. By Distribution Channel
12.21. PEST Analysis
12.22. Key Trend
12.23. Key Development

13. Middle East & Africa Rheumatoid Arthritis Drugs Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Rheumatoid Arthritis Drugs Market Overview
13.3. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
13.4. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
13.6. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
13.6.1. Disease-modifying anti-rheumatic drugs (DMARDs)
13.6.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
13.6.3. Corticosteroids
13.6.4. Biologic response modifiers (biologics)
13.7. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
13.8. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Rheumatoid Arthritis Drugs Market Analysis, by Country
13.10. GCC Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
13.10.1. Hospital Pharmacy
13.10.2. Retail Pharmacy
13.10.3. Online Pharmacy
13.11. GCC Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
13.11.1. Disease-modifying anti-rheumatic drugs (DMARDs)
13.11.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
13.11.3. Corticosteroids
13.11.4. Biologic response modifiers (biologics)
13.12. South Africa Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
13.12.1. Hospital Pharmacy
13.12.2. Retail Pharmacy
13.12.3. Online Pharmacy
13.13. South Africa Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
13.13.1. Disease-modifying anti-rheumatic drugs (DMARDs)
13.13.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
13.13.3. Corticosteroids
13.13.4. Biologic response modifiers (biologics)
13.14. Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
13.14.1. Hospital Pharmacy
13.14.2. Retail Pharmacy
13.14.3. Online Pharmacy
13.15. Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
13.15.1. Disease-modifying anti-rheumatic drugs (DMARDs)
13.15.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
13.15.3. Corticosteroids
13.15.4. Biologic response modifiers (biologics)
13.16. Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis
13.16.1. By Drug Type
13.16.2. By Distribution Channel
13.17. PEST Analysis
13.18. Key Trend
13.19. Key Development

14. South America Rheumatoid Arthritis Drugs Market Analysis
14.1. Key Findings
14.2. South America Rheumatoid Arthritis Drugs Market Overview
14.3. South America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
14.4. South America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
14.4.1. Hospital Pharmacy
14.4.2. Retail Pharmacy
14.4.3. Online Pharmacy
14.5. South America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
14.6. South America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
14.6.1. Disease-modifying anti-rheumatic drugs (DMARDs)
14.6.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
14.6.3. Corticosteroids
14.6.4. Biologic response modifiers (biologics)
14.7. South America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
14.8. South America Rheumatoid Arthritis Drugs Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. Brazil Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
14.9.1. Hospital Pharmacy
14.9.2. Retail Pharmacy
14.9.3. Online Pharmacy
14.10. Brazil Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
14.10.1. Disease-modifying anti-rheumatic drugs (DMARDs)
14.10.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
14.10.3. Corticosteroids
14.10.4. Biologic response modifiers (biologics)
14.11. Mexico Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
14.11.1. Hospital Pharmacy
14.11.2. Retail Pharmacy
14.11.3. Online Pharmacy
14.12. Mexico Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
14.12.1. Disease-modifying anti-rheumatic drugs (DMARDs)
14.12.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
14.12.3. Corticosteroids
14.12.4. Biologic response modifiers (biologics)
14.13. Rest of South America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
14.13.1. Hospital Pharmacy
14.13.2. Retail Pharmacy
14.13.3. Online Pharmacy
14.14. Rest of South America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
14.14.1. Disease-modifying anti-rheumatic drugs (DMARDs)
14.14.2. Non-steroidal anti-inflammatory drugs (NSAIDs)
14.14.3. Corticosteroids
14.14.4. Biologic response modifiers (biologics)
14.15. South America Rheumatoid Arthritis Drugs Market Attractiveness Analysis
14.15.1. By Drug Type
14.15.2. By Distribution Channel
14.16. PEST Analysis
14.17. Key Trend
14.18. Key Development

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
15.3. Company Profiles: Key Players
15.3.1. AbbVie Inc.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint
15.3.2. Boehringer Ingelheim GmbH
15.3.3. Novartis AG
15.3.4. Regeneron Pharmaceuticals, Inc.
15.3.5. Pfizer, Inc.
15.3.6. Johnson & Johnsons Services, Inc
15.3.7. Bristol-Myers Squibb Company
15.3.8. F. Hoffmann-La Roche Ltd.
15.3.9. Celegene Corporations
15.3.10. MedImmune, LLC
15.3.11. Takeda Pharmaceutical Company Ltd.
15.3.12. Biogen Inc.
15.3.13. Celltrion Inc.
15.3.14. Janssen Biotech, Inc.
15.3.15. Amgen, Inc.
15.3.16. Eli Lily and company
15.3.17. Merck & Co. Inc.
15.3.18. UCB S.A.
15.3.19. Sobi, Inc.
15.3.20. Gilead Science Inc.

16. Primary Key Insights
  • INQUIRE BEFORE BUYING